A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
Inserm · Hôpital Cochin · +22 more institutions
Abstract
The use of intensive lipid-lowering therapy by means of statin medications is recommended after transient ischemic attack (TIA) and ischemic stroke of atherosclerotic origin. The target level for low-density lipoprotein (LDL) cholesterol to reduce cardiovascular events after stroke has not been well studied.
In this parallel-group trial conducted in France and South Korea, we randomly assigned patients with ischemic stroke in the previous 3 months or a TIA within the previous 15 days to a target LDL cholesterol level of less than 70 mg per deciliter (1.8 mmol per liter) (lower-target group) or to a target range of 90 mg to 110 mg per deciliter (2.3 to 2.8 mmol per liter) (higher-target group). All the patients had evidence of cerebrovascular or coronary-artery atherosclerosis and received a statin, ezetimibe, or both. The composite primary end point of major cardiovascular events included ischemic stroke, myocardial infarction, new symptoms leading to urgent coronary or carotid revascularization, or death from cardiovascular causes.
Citation impact
- FWCI
- 59.37
- Percentile
- 100%
- References
- 17
Authors
32- PAPierre AmarencoCorresponding
Inserm, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Laboratoire de Recherche Vasculaire Translationnelle
- KJKim Js
Inserm, Asan Medical Center, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris
- JLJulien Labreuche
Inserm, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Laboratoire de Recherche Vasculaire Translationnelle
- HCHugo Charles
Inserm, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Laboratoire de Recherche Vasculaire Translationnelle
- JAJérémy Abtan
Inserm, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Laboratoire de Recherche Vasculaire Translationnelle
Topics & keywords
- Ischemic stroke
- Medicine
- Internal medicine
- Cardiology
- Stroke (engine)
- Cholesterol
- Statin
- Ldl cholesterol
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- MMerck
- SSanofi
- BBiogen
- TPTeva Pharmaceutical Industries
- CCelgene
- BSBoston Scientific Corporation
- SStryker
- RPRegeneron Pharmaceuticals
- MMMassachusetts Medical Society
- ACAmarin Corporation
- EEisai
- NNNovo Nordisk
- MDMinistère des Affaires Sociales et de la SantéAward: AOM09002
- OPOtsuka Pharmaceutical
- SServier
- IPIdorsia Pharmaceuticals
- MSMerck Sharp and Dohme
- AVAbbott Vascular
- BKBayer Korea
- DSDaiichi Sankyo Europe